Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.

Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC.

Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5.

PMID:
30952988
2.

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.

Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK.

Nat Biomed Eng. 2019 Mar;3(3):230-245. doi: 10.1038/s41551-018-0334-7. Epub 2019 Jan 7.

3.

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer.

Askoxylakis V, Ferraro GB, Badeaux M, Kodack DP, Kirst I, Shankaraiah RC, Wong CSF, Duda DG, Fukumura D, Jain RK.

NPJ Breast Cancer. 2019 Jan 15;5:4. doi: 10.1038/s41523-018-0100-8. eCollection 2019.

4.

Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.

Arvanitis CD, Askoxylakis V, Guo Y, Datta M, Kloepper J, Ferraro GB, Bernabeu MO, Fukumura D, McDannold N, Jain RK.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8717-E8726. doi: 10.1073/pnas.1807105115. Epub 2018 Aug 27.

5.

Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green.

Carr JA, Franke D, Caram JR, Perkinson CF, Saif M, Askoxylakis V, Datta M, Fukumura D, Jain RK, Bawendi MG, Bruns OT.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4465-4470. doi: 10.1073/pnas.1718917115. Epub 2018 Apr 6.

6.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

7.

A cerebellar window for intravital imaging of normal and disease states in mice.

Askoxylakis V, Badeaux M, Roberge S, Batista A, Kirkpatrick N, Snuderl M, Amoozgar Z, Seano G, Ferraro GB, Chatterjee S, Xu L, Fukumura D, Duda DG, Jain RK.

Nat Protoc. 2017 Nov;12(11):2251-2262. doi: 10.1038/nprot.2017.101. Epub 2017 Oct 5.

8.

Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors.

Askoxylakis V, Arvanitis CD, Wong CSF, Ferraro GB, Jain RK.

Adv Drug Deliv Rev. 2017 Sep 15;119:159-174. doi: 10.1016/j.addr.2017.06.011. Epub 2017 Jun 22. Review.

PMID:
28648712
9.

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Askoxylakis V, Kodack DP, Ferraro GB, Jain RK.

Breast Cancer Res Treat. 2017 Sep;165(2):467-468. doi: 10.1007/s10549-017-4351-0. Epub 2017 Jun 22. No abstract available.

PMID:
28643019
10.

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK.

Sci Transl Med. 2017 May 24;9(391). pii: eaal4682. doi: 10.1126/scitranslmed.aal4682. Erratum in: Sci Transl Med. 2019 Jan 30;11(477):.

11.

Closing the gap: astrocytes and brain metastasis.

Ferraro GB, Kodack DP, Askoxylakis V, Jain RK.

Cell Res. 2016 Sep;26(9):973-4. doi: 10.1038/cr.2016.96. Epub 2016 Aug 12.

12.

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4.

13.

Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis.

Askoxylakis V, Hegenbarth P, Timke C, Saleh-Ebrahimi L, Debus J, Röder F, Huber PE.

Radiat Oncol. 2016 Feb 4;11:17. doi: 10.1186/s13014-016-0595-9.

14.

Solid stress and elastic energy as measures of tumour mechanopathology.

Nia HT, Liu H, Seano G, Datta M, Jones D, Rahbari N, Incio J, Chauhan VP, Jung K, Martin JD, Askoxylakis V, Padera TP, Fukumura D, Boucher Y, Hornicek FJ, Grodzinsky AJ, Baish JW, Munn LL, Jain RK.

Nat Biomed Eng. 2016;1. pii: 0004. doi: 10.1038/s41551-016-0004. Epub 2016 Nov 28.

15.

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.

Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA, Jain RK.

J Natl Cancer Inst. 2015 Nov 7;108(2). pii: djv313. doi: 10.1093/jnci/djv313. Print 2016 Feb.

16.

Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.

Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, Dimitrakopoulou G, Debus J, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):127-42. eCollection 2015.

17.

Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.

Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK.

J Natl Cancer Inst. 2015 Feb 20;107(4). pii: djv017. doi: 10.1093/jnci/djv017. Print 2015 Apr.

18.

Emerging strategies for treating brain metastases from breast cancer.

Kodack DP, Askoxylakis V, Ferraro GB, Fukumura D, Jain RK.

Cancer Cell. 2015 Feb 9;27(2):163-75. doi: 10.1016/j.ccell.2015.01.001. Review.

19.

Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer.

Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, Zwicker F, Debus J, Timke C, Huber PE.

Radiat Oncol. 2014 Aug 29;9:191. doi: 10.1186/1748-717X-9-191.

20.

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis.

Askoxylakis V, Tanner J, Kappes J, Hoffmann H, Nicolay NH, Rief H, Debus J, Thomas M, Bischof M.

BMC Cancer. 2014 Aug 7;14:572. doi: 10.1186/1471-2407-14-572.

21.

Screening of a novel peptide targeting the proteoglycan-like region of human carbonic anhydrase IX.

Rana S, Nissen F, Lindner T, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V.

Mol Imaging. 2013 Nov-Dec;12(8). doi: 10.2310/7290.2013.00066.

PMID:
24447616
22.

Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials.

Rahbari NN, Elbers H, Askoxylakis V, Motschall E, Bork U, Büchler MW, Weitz J, Koch M.

Ann Surg Oncol. 2013 Dec;20(13):4169-82. doi: 10.1245/s10434-013-3198-9. Epub 2013 Sep 4.

PMID:
24002536
23.

The stability of osseous metastases of the spine in lung cancer--a retrospective analysis of 338 cases.

Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, Lindel K, Combs S, Debus J.

Radiat Oncol. 2013 Aug 13;8(1):200. doi: 10.1186/1748-717X-8-200.

24.

Peptide arrays for development of PDGFRβ Affine molecules.

Marr A, Nissen F, Maisch D, Altmann A, Rana S, Debus J, Huber PE, Haberkorn U, Askoxylakis V.

Mol Imaging Biol. 2013 Aug;15(4):391-400. doi: 10.1007/s11307-013-0616-0.

PMID:
23381728
25.

Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.

Askoxylakis V, Ehemann V, Rana S, Krämer S, Rahbari NN, Debus J, Haberkorn U.

Int J Mol Sci. 2012 Oct 11;13(10):13030-48. doi: 10.3390/ijms131013030.

26.

Combination of phage display and molecular grafting generates highly specific tumor-targeting miniproteins.

Zoller F, Markert A, Barthe P, Zhao W, Weichert W, Askoxylakis V, Altmann A, Mier W, Haberkorn U.

Angew Chem Int Ed Engl. 2012 Dec 21;51(52):13136-9. doi: 10.1002/anie.201203857. Epub 2012 Nov 13.

PMID:
23150222
27.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

28.

Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.

Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, Dimitrakopoulou-Strauss A, Kopp-Schneider A, Haberkorn U, Huber PE, Bischof M, Debus J, Thieke C.

Radiat Oncol. 2012 Sep 14;7:157. doi: 10.1186/1748-717X-7-157.

29.

Peptide-based targeting of the platelet-derived growth factor receptor beta.

Askoxylakis V, Marr A, Altmann A, Markert A, Mier W, Debus J, Huber PE, Haberkorn U.

Mol Imaging Biol. 2013 Apr;15(2):212-21. doi: 10.1007/s11307-012-0578-7.

30.

Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.

Rana S, Nissen F, Marr A, Markert A, Altmann A, Mier W, Debus J, Haberkorn U, Askoxylakis V.

PLoS One. 2012;7(5):e38279. doi: 10.1371/journal.pone.0038279. Epub 2012 May 31.

31.

Simultaneous integrated boost for adjuvant treatment of breast cancer--intensity modulated vs. conventional radiotherapy: the IMRT-MC2 trial.

Askoxylakis V, Jensen AD, Häfner MF, Fetzner L, Sterzing F, Heil J, Sohn C, Hüsing J, Tiefenbacher U, Wenz F, Debus J, Hof H.

BMC Cancer. 2011 Jun 15;11:249. doi: 10.1186/1471-2407-11-249.

32.

Biotechnology techniques for the development of new tumor specific peptides.

Marr A, Markert A, Altmann A, Askoxylakis V, Haberkorn U.

Methods. 2011 Nov;55(3):215-22. doi: 10.1016/j.ymeth.2011.05.002. Epub 2011 May 27. Review.

PMID:
21640826
33.

Molecular imaging of tumor metabolism and apoptosis.

Haberkorn U, Markert A, Mier W, Askoxylakis V, Altmann A.

Oncogene. 2011 Oct 6;30(40):4141-51. doi: 10.1038/onc.2011.169. Epub 2011 May 16. Review.

PMID:
21577202
34.

Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency.

Askoxylakis V, Millonig G, Wirkner U, Schwager C, Rana S, Altmann A, Haberkorn U, Debus J, Mueller S, Huber PE.

Radiat Oncol. 2011 Apr 10;6:35. doi: 10.1186/1748-717X-6-35.

35.

Challenges in optimizing a prostate carcinoma binding peptide, identified through the phage display technology.

Askoxylakis V, Zitzmann-Kolbe S, Zoller F, Altmann A, Markert A, Rana S, Marr A, Mier W, Debus J, Haberkorn U.

Molecules. 2011 Feb 14;16(2):1559-78. doi: 10.3390/molecules16021559.

36.

A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.

Askoxylakis V, Garcia-Boy R, Rana S, Krämer S, Hebling U, Mier W, Altmann A, Markert A, Debus J, Haberkorn U.

PLoS One. 2010 Dec 31;5(12):e15962. doi: 10.1371/journal.pone.0015962.

37.

[Iodide enrichment in malignant tumours after gene transfer].

Haberkorn U, Askoxylakis V, Markert A, Altmann A.

Nuklearmedizin. 2010;49 Suppl 1:S21-5. German.

PMID:
21152690
38.

Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.

Altmann A, Eisenhut M, Bauder-Wüst U, Markert A, Askoxylakis V, Hess-Stumpp H, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2286-97. doi: 10.1007/s00259-010-1573-3. Epub 2010 Aug 3.

PMID:
20680269
39.

Long-term survival of cancer patients compared to heart failure and stroke: a systematic review.

Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M.

BMC Cancer. 2010 Mar 22;10:105. doi: 10.1186/1471-2407-10-105. Review.

40.

Patterns of failure after stereotactic radiotherapy of intracranial meningioma.

Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S.

J Neurooncol. 2010 Jul;98(3):367-72. doi: 10.1007/s11060-009-0084-1. Epub 2009 Dec 13.

PMID:
20012910
41.

Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients.

Bertsche T, Askoxylakis V, Habl G, Laidig F, Kaltschmidt J, Schmitt SP, Ghaderi H, Bois AZ, Milker-Zabel S, Debus J, Bardenheuer HJ, Haefeli WE.

Pain. 2009 Dec 15;147(1-3):20-8. doi: 10.1016/j.pain.2009.07.009. Epub 2009 Aug 19.

PMID:
19695779
42.

Characterization and development of a peptide (p160) with affinity for neuroblastoma cells.

Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Krämer S, Beck C, Schwab M, Eisenhut M, Haberkorn U.

J Nucl Med. 2006 Jun;47(6):981-8.

43.

Preclinical evaluation of the breast cancer cell-binding peptide, p160.

Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RH, Schwab M, Eisenhut M, Haberkorn U.

Clin Cancer Res. 2005 Sep 15;11(18):6705-12.

44.

A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy.

Zitzmann S, Mier W, Schad A, Kinscherf R, Askoxylakis V, Krämer S, Altmann A, Eisenhut M, Haberkorn U.

Clin Cancer Res. 2005 Jan 1;11(1):139-46.

Supplemental Content

Loading ...
Support Center